NSCLC in stage IV with oligo metastases
Conditions
Interventions
A:treatment Oligometastases and radiotherapy
Sponsors
Henan anti-cancer hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. voluntary and signed written informed consent; 2. aged 18 to 75 years, sex not limited; 3. pathology or cytology in the diagnosis of NSCLC (squamous cell carcinoma, adenocarcinoma and large cell carcinoma); 4. primary tumors can measure; 5. distant organ metastases number 70; 7. survival is expected to exceed 3 months; 8. reproductive age women should ensure that before entering the study period contraception; 9. HB >=100 g/L, WBC >=4*1089/L, platelet >=100*10^9/L; 10. liver function: the upper limit of normal value of ALT, AST< (ULN) 1.5 times, total bilirubin <1.5*ULN; 11. renal function: serum creatinine <1.5*ULN; 12. patients have good compliance to treatment and follow-up of acceptance.
Exclusion criteria
Exclusion criteria: 1. Do not meet the inclusion criteria for patients with pathologic type and primary site; 2. to pemetrexed, cisplatin, docetaxel and contrast medium allergy; 3. distant organ metastases number > 5; 4. the primary tumor, lymph node and metastases has underwent surgical operation (biopsy except); 5. the primary tumor, lymph node and metastases had radiotherapy; 6. had molecular targeted therapy; 7. had received chemotherapy or immunotherapy; 8. suffered from other malignant tumors; 9. in January received other drug test subjects; 10. pregnant or lactating women and treatment observation period rejected contraception in female; 11. There was serious allergic or idiosyncratic. History, serious pulmonary heart disease; 12. refused or not signed the informed consent to participate in trials; 13. abuse drugs or alcohol addicts; 14. personality or psychiatric disorders, no civil capacity or with limited civil capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size; | — |
Countries
China
Contacts
Public ContactJianjun Qin
Outcome results
None listed